(0.80%) 5 277.51 points
(1.51%) 38 686 points
(-0.01%) 16 735 points
(-0.94%) $77.18
(0.35%) $2.58
(-0.79%) $2 347.70
(-3.10%) $30.56
(0.63%) $1 044.50
(-0.17%) $0.921
(-0.49%) $10.49
(-0.05%) $0.785
(0.15%) $90.40
Live Chart Being Loaded With Signals
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer...
Stats | |
---|---|
今日成交量 | 35 078.00 |
平均成交量 | 22 265.00 |
市值 | 74.40M |
EPS | $0 ( 2024-05-10 ) |
下一个收益日期 | ( $-0.500 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0.0170 (0.89%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-10 | Dawes Karen A | Buy | 19 516 | Share Option (Right to Buy) |
2024-05-10 | Scheeren Joseph | Buy | 19 516 | Share Option (Right to Buy) |
2024-05-10 | Phillips Anne M. | Buy | 19 516 | Share Option (Right to Buy) |
2024-05-10 | Hammacher Alex | Buy | 19 516 | Share Option (Right to Buy) |
2024-05-10 | Morgon Pierre A. | Buy | 19 516 | Share Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 6 transactions |
Buy: 117 096 | Sell: 0 |
Barinthus Biotherapeutics 财务报表
Annual | 2023 |
营收: | $805 108 |
毛利润: | $802 000 (99.61 %) |
EPS: | $-1.920 |
FY | 2023 |
营收: | $805 108 |
毛利润: | $802 000 (99.61 %) |
EPS: | $-1.920 |
FY | 2022 |
营收: | $44.70M |
毛利润: | $44.70M (100.00 %) |
EPS: | $0.140 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。